# Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

> **NCT04428671** · PHASE1 · RECRUITING · sponsor: **Emory University** · enrollment: 20 (estimated)

## Conditions studied

- Metastatic Skin Squamous Cell Carcinoma
- Recurrent Skin Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Cemiplimab
- **RADIATION:** Radiation Therapy
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT04428671
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-15
- **Primary completion:** 2030-10-01
- **Final completion:** 2031-10-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04428671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04428671, "Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04428671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*